By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TapImmune Inc. 

2815 Eastlake Avenue East
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 866-359-7541 Fax: n/a




Company News
TapImmune (TPIV) Announces Reverse Stock Split In Preparation For Proposed Uplisting To NASDAQ Capital Market 9/15/2016 10:04:49 AM
TapImmune (TPIV) Issues Update: Multiple Phase 2 Trials, Over $9 Million In New Funding & NASDAQ Uplisting Application 9/6/2016 8:28:12 AM
TapImmune (TPIV) Appoints Michael J. Loiacono As Chief Financial Officer 8/25/2016 10:00:55 AM
TapImmune (TPIV) Enters Into Definitive Agreements To Raise $8.5 Million From The Exercise Of Outstanding Warrants And In A Private Placement From New Investors 8/11/2016 7:26:31 AM
TapImmune (TPIV) Appoints Dr. John N. Bonfiglio As President And Chief Operating Officer 7/19/2016 7:23:40 AM
TapImmune (TPIV) Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200 6/21/2016 7:01:34 AM
TapImmune (TPIV) Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine 6/7/2016 10:26:01 AM
TapImmune (TPIV) To Present At The LD Micro Invitational In Los Angeles On June 7, 2016 6/6/2016 4:07:05 PM
TapImmune (TPIV) To Present At The 3rd Annual Growth Capital Expo In Las Vegas On May 4, 2016 4/28/2016 9:59:03 AM
TapImmune (TPIV) Announces Phase 2 Ovarian Cancer Trial Study With AstraZeneca PLC (AZN)/MedImmune (AZN) And Sloan Kettering Cancer Institute 4/21/2016 7:47:16 AM